Northwire Canada EditionFriday, July 10, 2026
Sign inSubscribe
Northwire
⌕
S 0.165 +37.5% NNX 0.035 +0.0% ABX 52.04 −0.3% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.27 +11.9% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.51 +1.2% SGZ 0.040 −11.1% GRSL 0.307 −3.9% DEX 0.380 −1.3% WMS 0.040 +0.0% S 0.165 +37.5% NNX 0.035 +0.0% ABX 52.04 −0.3% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.27 +11.9% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.51 +1.2% SGZ 0.040 −11.1% GRSL 0.307 −3.9% DEX 0.380 −1.3% WMS 0.040 +0.0%
Production / Operations Routine +

MustGrow Receives Georgia Registration for TerraSante(TM) Biofertility Product

MustGrow Expands U.S. Footprint with Georgia Registration Amidst Revenue Scaling Challenges

By The Northwire Desk — AI Analysis Apr 28, 2026 · 07:01 MGRO · 0.57 MustGrow Biologics Corp.
Executive Summary
  • MustGrow Biologics Corp. received registration approval from the Georgia Department of Agriculture for its TerraSante(TM) organic biofertility product.
  • This expansion allows sales in Georgia, complementing existing registrations in California, Florida, Arizona, Idaho, Oregon, and Washington State.
  • The product is a mustard-derived wettable powder designed to improve soil microbiome health and crop yields.
  • Target markets include high-value crops such as peanuts ($762 million USD cash receipts), pecans ($184 million), and blueberries ($156 million).
  • Approval leverages existing Organic OMRI Listed® certifications and California's OIM Program status.
Material Impact
  • The news represents an incremental step in the company's commercialization roadmap rather than a sudden market-moving event.
  • Regulatory approvals for biofertilizers are typically sequential state-by-state processes; Georgia was anticipated following previous U.S. expansions mentioned in December 2025 communications.
  • While Georgia is a significant agricultural market, registration alone does not guarantee immediate revenue volume without confirmed sales contracts or distribution agreements.
  • The stock price has already reacted to prior financing and trial data (January 2026 spike to $0.90 followed by decline), suggesting this specific regulatory milestone may be partially priced in.
  • No new strategic investors, M&A activity, or major contract wins are disclosed that would elevate this to a "Game Changer" status.
MGRO · Price
Company Overview
  • MustGrow Biologics Corp. develops mustard-derived biofertilizers and biocontrol products for agriculture.
  • Flagship Product (TerraSante): Organic biofertility product registered in 7 U.S. states; designed to improve soil health and yield efficiency.
  • Secondary Product (TerraMG): Biocontrol product targeting clubroot disease in canola, currently undergoing field trials and Health Canada registration.
  • Distribution Arm: NexusBioAg serves as the Canadian sales and distribution channel for TerraMG.
  • Manufacturing: Scaling capacity via contract manufacturers in Asia to meet growing demand and improve margins.
Read the original news release →

More from MustGrow Biologics Corp.

Jun 19, 2026 · 17:01

MustGrow Biologics Raises $3.7M to Fund TerraSante Biofertility Ramp Amid Persistent Cash Burn

Financings Jun 17, 2026 · 19:22

MustGrow Biologics raises $3.7M to fund TerraSante ramp-up amid persistent cash burn.

Financings May 28, 2026 · 17:01

MustGrow Biologics Secures Liquidity Amidst Early Revenue Growth and Manufacturing Transition

Earnings May 25, 2026 · 18:01

MustGrow Biologics Secures Capital for U.S. Expansion Amidst Revenue Growth

Financings May 25, 2026 · 07:00

Regulatory Expansion Validates Growth Strategy But Cash Burn Remains Critical Risk

Regulatory May 14, 2026 · 17:15

MustGrow Biologics Corp.

Other